Nasdaq

U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has granted approval for Tecartus ® for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Business Wire

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia | Business Wire

ATLANTA--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, ...
Nasdaq

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic ...

-- If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients (18 Years and Older) with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia -- In ...

Giant kites fill Omaha sky at inaugural Heartwood Preserve festival

Omaha’s sky came alive with giant kites this weekend, some as big as school buses, as hundreds of people attended the ...